deaths (OS)

metastatic (mCRPC) - 1st line (L1) castration-resistant prostate cancer (CRPC) metastatic (mCRPC) - 1st line (L1)

versus placebo
ipilimumab alone vs. placebo 2 -883 [-1504; -262] /10000
269/399 vs. 305/400

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer